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xidized or Native Low-
ensity Lipoprotein Cholesterol
hich Is More
mportant in Atherogenesis?*
awahar L. Mehta, MD, PHD, FACC
ittle Rock, Arkansas
therosclerosis and related disorders are the major causes
f morbidity and mortality in the Western world.
therosclerosis-related diseases are also becoming common
n the developing world. The Framingham study and other
pidemiologic studies have amply shown that certain condi-
ions are associated with atherogenesis and are appropriately
alled risk factors. These include age, gender, dyslipidemias
such as high low-density lipoprotein [LDL]-cholesterol, low
igh-density lipoprotein [HDL]-cholesterol, high triglycer-
des, and various permutations of lipid abnormalities), cigarette
moking, hypertension, and diabetes. On the basis of the
trong association of these risk factors with atherosclerosis-
elated events, prevention as well as therapeutic strategies have
een directed at modification of these conditions. Implemen-
ation of these strategies has led to major health benefits, in
erms of reduction in death from stroke and myocardial
nfarction (MI) over the last 2 decades in the U.S. (1).
See page 973
Various other conditions or risk states have also been
roposed as markers of atherosclerosis and related events
2–4). These include hyperhomocysteinemia, prothrom-
otic state, infections (such as C. pneumonia, H. pylori, and
erpes virus), endothelial dysfunction, state of inflamma-
ion, and oxidative stress. Attempts are being made to
evelop new specific biomarkers that will facilitate identifi-
ation of individuals at risk, therapeutic targets, response to
herapy, and prognosis (2,3).
Of these novel risk states, inflammation and oxidative
tress have attracted most attention. Inflammation is invari-
bly present in all atherosclerotic regions, with preponder-
nce in regions that are likely to rupture and predispose the
atient to develop an acute event. Furthermore, many
tudies (5–8) have shown a predictive value of a host of
nflammatory markers, such as cytokines (tumor necrosis
actor, interleukin-6, and interleukin-18), serum amyloid
, C-reactive protein (CRP), myeloperoxidase, and
hite blood cell count. However, the predictive value of
*Editorials published in the Journal of American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.w
From the Department of Internal Medicine, University of Arkansas for Medical
ciences and Central Arkansas Veterans Healthcare System, Little Rock, Arkansas.hese markers has varied markedly. Whether inflamma-
ion represents a primary pathogenic stimulus in athero-
enesis or a mere response to vascular injury caused by
ypertension, dyslipidemia, and hyperglycemia continues
o be debated (9).
Recently, there has also been much interest in the
ro-oxidant state in atherosclerosis-related vascular disease
tates and aging (10). An oxidant state implies that the
ody’s endogenous antioxidants are not sufficient to neu-
ralize the oxidant species. The concept of a pathogenic role
f oxidants is particularly attractive, because oxidant species
njure endothelial cells, denature the vasodilator species
itric oxide, induce inflammation and thrombosis, and
xidize LDL cholesterol, all of which accompany athero-
enesis. Furthermore, a number of studies in animal and cell
odel systems have shown protective effects of a variety of
ntioxidants, including tocopherols and ascorbic acid (11–
3). Melov et al. (14) showed a marked prolongation in the
ife-span of C. elegans with administration of a superoxide
imutase/catalase mimetic. However, clinical trials of com-
on antioxidants have by and large shown no benefit (15).
his implies that either the oxidant/antioxidant imbalance
s not pivotal in atherogenesis or appropriate antioxidant
ormulations have not been used.
A number of studies suggest that the oxidized low-
ensity lipoprotein (ox-LDL) is a more potent pro-
therosclerotic stimulus than the native unmodified LDL.
ndothelium exposed to ox-LDL develops early signs of
njury, such as apoptosis (16). The ox-LDL decreases the
ene expression of endothelial nitric oxide synthase (eNOS)
nd enhances generation of reactive oxygen species (17).
he ox-LDL itself activates inflammatory cells and facili-
ates release of growth factors from monocytes/macrophages
18,19). Platelet eNOS activity is diminished in the pres-
nce of ox-LDL, and these cells demonstrate intense
ctivation in response to small amounts of thrombin (20).
he ox-LDL also increases formation of metalloprotein-
ses, thus setting the stage for rupture of a soft plaque.
ecent studies have shown that ox-LDL stimulates expres-
ion of CD40/CD40L in endothelial cells and release
ytokines (21). Other studies have shown that ox-LDL
pregulates the expression of various components of the
enin-angiotensin system, such as angiotensin-converting
nzyme and angiotensin II type 1 receptors in endothelial
nd vascular smooth muscle cells (22,23). Most importantly,
athologic studies have shown accumulation of ox-LDL in
he rupture-prone atherosclerotic plaque (24).
Given the obvious pathophysiologic significance, there
as been intense interest in the measurement of ox-LDL or
ntibodies to ox-LDL as predictor of coronary heart disease
CHD) events (25–29). In a nested case-control study in
ndividuals with and without elevated LDL cholesterol
evels, ox-LDL levels were found to be increased in patients
ho subsequently developed MI (25). In another study,
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September 5, 2006:980–2 Editorial Commentatients with angiographic coronary artery disease had
igher levels of ox-LDL and higher global risk assessment
cores than the age-matched control subjects (26). In a
arger cohort of individuals, the odds ratio for CHD risk
as 2.79 in the top compared with the lower quintile after
djusting for age, gender, race, LDL cholesterol, smoking
tatus, and CRP (27). In keeping with this information, a
ecent study showed higher plasma levels of circulating
ectin-like oxidized LDL (LOX-1), a specific ox-LDL
eceptor on endothelial cells, in patients with acute coronary
yndromes (28). Importantly, LOX-1 levels in plasma had
igher predictive value than did the CRP levels.
In this regard, the study by Wu et al. (29) in this issue of
he Journal is particularly important. They identified 266
en and 235 women from the Health Professionals
ollow-up Study and the Nurses’ Health Study. These
ndividuals had incident MI or fatal CHD, and each index
atient was matched with two control subjects by age and
moking status. Plasma ox-LDL levels in these individuals
ere significantly related to the risk of coronary artery
isease in multivariate analysis. However, when ox-LDL,
DL cholesterol, HDL cholesterol, and triglyceride levels
ere mutually adjusted, ox-LDL levels were no longer
redictive. Importantly, apolipoprotein B, total/HDL cho-
esterol, and other conventional lipid markers, including
DL cholesterol, HDL cholesterol, and triglycerides, re-
ained powerful differentiating factors.
There are many limitations of this study, including use of
single blood draw; ill-defined nature of the antibody
gainst an isotope in the ox-LDL–moiety in the ox-LDL
it used in this study; lack of information on patients’
herapy, especially use of antioxidants; and most impor-
antly, the retrospective nature of the study. As recognized
y the authors, prospective studies need to be performed,
specially in individuals not receiving antioxidants, to de-
ermine the value of ox-LDL measurements in predicting
HD events. Further studies will need to be performed to
ocument that ox-LDL measurements are reproducible in
he same subject over time; are reliable when frozen and
tored samples are used; and, very critically, provide value
bove and beyond what is available from global assessment
lgorithms. In this regard, it is noteworthy that the
NTERHEART study on risk factors associated with MI in
2 countries identified smoking, high apolipoprotein
Apo)B/ApoA1 ratio, history of hypertension, diabetes,
bdominal obesity, psychosocial factors, low daily consump-
ion of fruits and vegetables, alcohol consumption, and lack
f physical activity as 9 major risk factors that define
opulation attributable risk in 90% of men and 94% of
omen (30). In essence, it is quite clear that oxidative stress
s present in various stages of CHD. Whether the biomar-
er will turn out to be ox-LDL, LOX-1, or some other
elated moiety needs to be determined. Naturally, one
ould expect any new biomarker to provide significant
dditional value for mass screening of populations at a low
ost.The author’s opinion about the role of various risk factors for
therosclerosis, including inflammation and oxidative stress, is
hown in Figure 1. Needless to say, genetic predisposition to
he development of disease might be a critical yet undefined
actor.
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